




The relative strengths and weaknesses of Sucampo Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sucampo Pharmaceuticals Inc compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 44% points. The greatest weakness of Sucampo Pharmaceuticals Inc is the variable Liabilities, reducing the Economic Capital Ratio by 96% points.

The company's Economic Capital Ratio, given in the ranking table, is 187%, being 47% points below the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	114,916
Cost of Goods Sold	0
Intangible Assets	8,364
Liabilities, Current	47,081
Liabilities, Non-Current	2,603
Other Assets	32,620
Other Compr. Net Income	1,280
Other Expenses	-6,925
Other Liabilities	69,291
Other Net Income	-4,225
Other Revenues	54,761
Property and Equipment	1,669
Research and Development	33,497
Selling, General and Administrative Expense	41,270

Output Variable	Value in 1000 USD
Assets	157,569
Liabilities	118,975
Expenses	67,842
Revenues	54,761
Stockholders Equity	38,594
Net Income	-17,306
Comprehensive Net Income	-16,666
BaseVar	202,326
ECR before LimitedLiability	49%
Economic Capital Ratio	187%